Table 2.
Clinical Characteristics at the Time of Torque Teno Virus Assessment for the Study Cohort and Stratified According to Kidney Allograft Biopsy Results
| Characteristic | Study Cohort (n = 113) |
Biopsy-Proven Alloreactivity (n = 33) |
No Acute Rejection (n = 80) |
P Value |
|---|---|---|---|---|
| Laboratory parameter | ||||
| eGFR, mL/min/1.73 m2, median (IQR)a | 36 (29–48) | 39 (33–50) | 36 (28–48) | .620 |
| Urinary protein:creatinine ratio, median (IQR) | 199 (129–483) | 193 (126–580) | 207 (131–446) | .627 |
| Microhematuriab | 36 (36) | 8 (29) | 28 (39) | .334 |
| Immunosuppression | ||||
| Triple immunosuppression | 105 (93) | 29 (88) | 76 (95) | .232 |
| Corticosteroid | 112 (99) | 33 (100) | 79 (99) | .519 |
| Prednisolone, mg, median (IQR) | 7.5 (5–10) | 7.5 (5–10) | 5 (5–5) | .420 |
| Mycophenolic acid | 96 (85) | 27 (82) | 69 (86) | .570 |
| Mycophenolic acid above medianc | 50 (54) | 13 (48) | 37 (57) | .442 |
| Tacrolimus | 99 (88) | 26 (84) | 73 (95) | .116 |
| Tacrolimus trough level, ng/mL, median (IQR) | 6.9 (5.4–9) | 6.7 (4.8–10) | 6.9 (5.5–9) | .558 |
| Belatacept | 5 (4) | 2 (6) | 3 (4) | .628 |
| Assessment of primary outcome parameters | ||||
| Biopsy, days after transplantation, median (IQR) | 186 (155–258) | 186 (157–264) | 186 (154–259) | .622 |
| TTV, days after transplantation, median (IQR) | 127 (105–174) | 121 (107–174) | 140 (103–174) | .877 |
| TTV assessment to biopsy, d, median (IQR) | 43 (22–96) | 43 (22–97) | 48 (15–89) | .786 |
Data are presented as No. (%) unless otherwise indicated. The Mann–Whitney U test was used for comparing continuous data and group comparisons were made using the χ2 test. Exact tests were used where applicable.
Abbreviations: eGFR, estimated glomerular filtration rate; IQR, interquartile range; TTV, teno torque virus.
aeGFR was calculated using the Modification of Diet in Renal Disease equation [7]. Data were available from 100 patients.
bMicrohematuria was assessed by dipstick analysis or light microscopy.
cFive hundred forty milligrams for enteric-coated mycophenolic acid and 1500 mg for non-enteric-coated mycophenolic acid. Data were available from 92 of 96 patients.